Search Results for "Bendamustine Myeloma"
Original Source: Efficacy of bendamustine in relapsed / refractory myeloma patients: results from the french compassionate use program.
Abstract One hundred and ten patients with multiple myeloma were treated with bendamustine as part of a French compassionate use program. To receive bendamustine, patients had to present with relapsed or refractory disease after prior therapies that had to include alkylators, steroids, IMiDs and bortezomib. The median number of bendamustine cycles administered was 4 (1-13). The overall response rate (≥ partial response) was 30%, including 2% complete responses. The median progression-free and overall surv...
Matching Channels
Myeloma is a malignant disease of the bone marrow. The features are an excess of abnormal malignant plasma cells in the bone marrow, lytic deposits on an X-ray and abnormal gammaglobulin in the seru...
The European Organization for Rare Diseases considers orphan diseases to be those that are rare (occur in 1 in 1500 to 1 in 2500 patients, according to US Rare Disease Act 2002 and European Commissi...
Fluorescent in situ hybridization (FISH) is a sensitive and accurate technique that allows the detection of chromosome aberrations. In this method, a single-stranded fluorescent-labeled nucleic acid...
The proteasome is involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune respon...
Matching News
BRIGHT Shines Light on R-Bendamustine in Lymphoma
At 50 years of age, bendamustine holds its own against standard regimens in lymphoma. Medscape Hematology-Oncology
Bendamustine Plus Rituximab Boost PFS in Indolent Lymphomas
The combination of bendamustine plus rituximab appears to be more effective and less toxic than standard therapy in indolent lymphomas. Medscape Medical News
Mundipharma to present bendamustine data at ASH meeting
Mundipharma will present 43 abstracts, which include the study results of bendamustine involved in a number of lymphoid malignancies at the 54th Annual Meeting of the American Society of Hematology (A...
Myeloma UK Funded Research Leads To Breakthrough In Understanding Causes Of Myeloma Cancer
The Myeloma UK funded Research Programme at The Institute of Cancer Research (ICR) has made another important discovery about the genetics of myeloma. Researchers at the ICR have identified an inherit...
More data needed in Japan for SymBio's bendamustine in aggressive NHL
SymBio Pharmaceuticals has said that it will need to generate additional clinical data to support a planned regulatory filing in Japan for its anticancer product Treakisym (bendamustine) in the addit...
Myeloma bone disease: background and latest
Prof Evangelos Terpos and Prof Michel Delforge talk at the 14th International Myeloma Workshop, 3-7th May 2013, Kyoto. Myeloma bone disease (MBD) is the most common complication of multiple myeloma (...
Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; p Results from the StiL NHL-1 study pub...
ecancertv talks to Eric Low at IMW 2013, Kyoto, Japan, 3-7th April Myeloma UK is a registered charity and is the only organisation in the UK dealing exclusively with myeloma. They are attending IMW...
Matching PubMed Articles
United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma.
Bendamustine is a unique bifunctional alkylating agent with promising activity in myeloma. Despite the increasing number of studies demonstrating its efficacy in both the upfront and relapse settings,...
Abstract One hundred and ten patients with multiple myeloma were treated with bendamustine as part of a French compassionate use program. To receive bendamustine, patients had to present with relapsed...
Bendamustine, active in multiple myeloma (MM), is a bifunctional mechlorethamine derivative with alkylating properties. Bortezomib, approved to treat MM, is effective in combination with alkylators. T...
Decrease in venous irritation by adjusting the concentration of injected bendamustine.
Intravenous injection of bendamustine often causes venous irritation and also deteriorates the patient's quality of life. Thus, we evaluated the risk factors associated with venous irritation induced...
Bendamustine and bendamustine/rituximab combinations have shown high efficacy in relapsed/refractory chronic lymphocytic leukemia (CLL) and indolent B-cell malignancies (non-Hodgkin lymphoma, NHL). No...
